Avidity Biosciences
RNAM
RNAM was delisted on the 26th of February, 2026.
52 hedge funds and large institutions have $702M invested in Avidity Biosciences in 2020 Q2 according to their latest regulatory filings, with 52 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
67.87% more ownership
Funds ownership: 0% → 67.87% (+68%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RI
RTW Investments
New York
|
+$115M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$81.7M |
| 3 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$72.5M |
| 4 |
EC
EcoR1 Capital
San Francisco,
California
|
+$60.7M |
| 5 |
PA
Perceptive Advisors
New York
|
+$35.6M |
Top Sellers
RNAM Hedge Fund Activity: Q2 2020 in Review
52 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Avidity Biosciences (RNAM) for Q2 2020, worth a combined $702M.
Buyers outnumbered sellers: 52 funds opened new RNAM positions and 0 closed out — a net gain of 52 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was RTW Investments, opening a new position worth an estimated $115M.
- 52 institutional investors held Avidity Biosciences (RNAM) as of Q2 2020, up from 0 in Q1 2020.
- Funds reported $702M of Avidity Biosciences stock for Q2 2020.
- 52 funds opened new Avidity Biosciences positions in Q2 2020 and 0 closed out, a net change of +52 holders.
- The largest Avidity Biosciences buyer in Q2 2020 was RTW Investments, an estimated $115M added.
Based on aggregated 13F filings for Q2 2020.